Get started
Author

Katherine Gano

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
2023 · Matthew Ingham, Jacob B. Allred, et al. · Journal of Clinical Oncology · 51
PDF
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
2015 · Joseph R. Mikhael, Craig B. Reeder, et al. · British Journal of Haematology · 46
Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
2017 · K. Gowin, H. Kosiorek, et al. · Leukemia Research · 43
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib ( MLN 8237) and Bortezomib in Relapsed Multiple Myeloma
2015 · Allison Rosenthal, Shaji Kumar, et al. · British Journal of Haematology · 27
PDF
Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma
2012 · Joseph R. Mikhael, Craig B. Reeder, et al. · Blood · 17
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy
2017 · Allison Rosenthal, Amylou C. Dueck, et al. · American Journal of Hematology · 16
PDF
A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort
2013 · Joseph R. Mikhael, Craig B. Reeder, et al. · Blood · 15
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
2021 · Matthew Ingham, Jacob B. Allred, et al. · Journal of Clinical Oncology · 12
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors
2023 · Meredith LaRose, Roisin M Connolly, et al. · The Oncologist · 9
Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis
2015 · Krisstina L. Gowin, Heidi E. Kosiorek, et al. · Blood · 9
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
2020 · Matthew Ingham, Jacob B Allred, et al. · Journal of Clinical Oncology · 6
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
2018 · Mohamad Bassam Sonbol, Talal Hilal, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
2014 · Krisstina L. Gowin, Amylou C. Dueck, et al. · Blood · 4
A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma
2014 · Allison C. Rosenthal, Amylou Constance Dueck, et al. · Blood · 2
A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy
2015 · Allison Rosenthal, Amylou C. Dueck, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results
2013 · Craig Reeder, Amylou Constance Dueck, et al. · Blood · 1
2022-RA-464-ESGO A phase i dose escalation and expansion cohort trial of carboplatin and gemcitabine with the ATR inhibitor berzosertib in first or second recurrence platinum sensitive epithelial ovarian, peritoneal, and fallopian tube cancer
2022 · Andrea E Wahner Hendrickson, Nathan Foster, et al. · International Journal of Gynecological Cancer
PDF
LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.
2012 · Craig Reeder, Stephen M Ansell, et al. · Blood
LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.
2012 · Craig B. Reeder, Rodger Edwin Tiedemann, et al. · Journal of Clinical Oncology
Works count: 19
Citation count: 264
H-index: 9
I10-index: 8
Year
Topic
Type